trial

Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors

NCTId NCT02008292
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 80 (actual)
Sponsored by Yale University
Primary completion 2021-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
80 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2013-09
Primary completion
2021-12
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Physostigmine

Sponsors

Yale UniversityLead Sponsor
National Institutes of Health (NIH)Collaborator
National Institute on Drug Abuse (NIDA)Collaborator

Investigators

1
Kelly Cosgrove, PhDPrincipal Investigator

Sites

3 total
New Haven, United StatesNew Haven, United StatesNew Haven, United States

Facts & assertions

4 sourced
Enrollment
80
Phase
NA
Primary Completion Date
2021-12
Status
COMPLETED
relationships
The graph out of here
drug
Physostigmine
drug
lead_sponsor
Yale University
company
collaborator
National Institutes of Health (NIH)
company
National Institute on Drug Abuse (NIDA)
company
indication
Smoking
indication
Schizophrenia
indication
Smoking
indication
investigator
Kelly Cosgrove, PhD
person